Tetsuya Mitsudomi 研究室

主宰者：Tetsuya Mitsudomi

近畿大学

AI 要約（直近 5 年の研究成果）

本研究室では、肺がん（特に非小細胞肺がん）の治療法の開発と最適化に取り組んでいます。特に注目する研究の問いは、完全切除された早期肺がんにおける再発予防法の確立、および治療抵抗性が生じるメカニズムの解明です。分子レベルの遺伝子変異（EGFR遺伝子変異やALK融合遺伝子など）に応じた個別化治療戦略の構築を目指しており、腫瘍に含まれるがん細胞の種類や免疫環境の違いが治療効果に与える影響を調べています。研究の手法としては、臨床試験データの解析、細胞培養モデルを用いた薬剤感受性検査、患者由来の移植腫瘍モデル、血液中の循環腫瘍DNAの測定、および単一細胞レベルの空間トランスクリプトーム解析など、多角的なアプローチを採用しています。特に、手術前の免疫療法や化学療法の組み合わせ効果、ならびに手術後の長期的な再発リスク追跡に関する大規模臨床研究を実施しており、実臨床への応用を重視しています。主な知見として、免疫チェックポイント阻害薬と化学療法の併用は、手術前投与により病理学的完全奏効率と無増悪生存を改善すること、EGFR遺伝子変異を有する患者においても免疫療法が有効である可能性があること、および標準治療に対する耐性機序に関わる複数の遺伝子変異パターンが存在することが報告されています。これらの成果は、肺がんの手術前後における治療効果の向上と個別化医療の実現に貢献しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（100 件）

[2026] Immunotherapy in resectable non–small cell lung cancer; emerging clinical questions
DOI: https://doi.org/10.1016/j.ijlcan.2026.100024
[2026] Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study)
DOI: https://doi.org/10.1016/j.jtocrr.2026.100967
[2026] Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1200/jco-25-01828
[2025] Figure S8 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708673
[2025] Figure S1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708700
[2025] Figure S7 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708676
[2025] Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708691
[2025] Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708685
[2025] Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708694
[2025] Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708688

続きを表示（残り 90 件）

[2025] Supplementary tables 1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708664
[2025] Figure S9 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708670
[2025] Figure S6 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708679
[2025] Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
DOI: https://doi.org/10.1158/2767-9764.crc-25-0186
[2025] Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study
DOI: https://doi.org/10.3390/cells14171386
[2025] Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2025.100897
[2025] Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)
DOI: https://doi.org/10.1016/j.jtho.2025.08.010
[2025] Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy
DOI: https://doi.org/10.1038/s41416-025-03088-0
[2025] Clinical utility of the 5-point visual Deauville score for preoperative evaluation in stage I non–small cell lung cancer: A multicenter retrospective study
DOI: https://doi.org/10.1016/j.jtcvs.2025.07.011
[2025] Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
DOI: https://doi.org/10.1016/j.jtho.2025.06.015
[2025] Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
DOI: https://doi.org/10.1200/jco.2025.43.17_suppl.lba8000
[2025] Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
DOI: https://doi.org/10.1056/nejmoa2502931
[2025] Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.8009
[2025] A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e20004
[2025] Abstract 4720: Evaluation of lorlatinib efficacy using plasma DNA
DOI: https://doi.org/10.1158/1538-7445.am2025-4720
[2025] Neoadjuvant Concurrent Chemo–Immuno–Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
DOI: https://doi.org/10.1016/j.jtho.2025.03.051
[2025] PP01.08 Pilot Study to Evaluate the Potential of the Tumor-Educated Platelets (TEP) as the Tool to Detect Minimal Residual Disease and Drug Resistance
DOI: https://doi.org/10.1016/j.jtho.2025.03.016
[2025] Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies
DOI: https://doi.org/10.1016/j.lungcan.2025.108437
[2025] Detection of Overlooked Rare <scp>EGFR</scp> Mutations in Non‐small Cell Lung Cancer Using Multigene Testing
DOI: https://doi.org/10.1111/1759-7714.70007
[2025] Staple Formations in Bronchial Closure with Equal-Height Staples to Those with Graduated-Height Staples Using Motorized Staplers
DOI: https://doi.org/10.5761/atcs.oa.25-00031
[2025] Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
DOI: https://doi.org/10.1200/jco-24-02239
[2025] Figure S10 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708697
[2025] Supplementary Data 1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708667
[2024] OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L)
DOI: https://doi.org/10.1016/j.jtho.2024.09.066
[2024] Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study
DOI: https://doi.org/10.1016/j.jtocrr.2024.100762
[2024] Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2024.108017
[2024] Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/2767-9764.crc-24-0212
[2024] P3.03H.03 Feasibility of Metastatic Lymph Node-informed ctDNA Analysis in Surgically Resected NSCLC Patients
DOI: https://doi.org/10.1016/j.jtho.2024.09.548
[2024] P4.07F.05 Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection
DOI: https://doi.org/10.1016/j.jtho.2024.09.696
[2024] EP.08F.05 Real World Evidence of Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: AYAME Study
DOI: https://doi.org/10.1016/j.jtho.2024.09.1085
[2024] EP.03B.04 Clinicopathological Features of Lung Cancers with RICTOR Gene Amplification
DOI: https://doi.org/10.1016/j.jtho.2024.09.817
[2024] Improved platelet separation performance from whole blood using an acoustic fluidics system
DOI: https://doi.org/10.1111/cas.16337
[2024] Savolitinib in NSCLC: progress in the MET exon 14 journey
DOI: https://doi.org/10.1016/s2213-2600(24)00258-3
[2024] Surgical outcomes with neoadjuvant Durvalumab+chemotherapy followed by adjuvant Durvalumab in resectable NSCLC (AEGEAN)
DOI: https://doi.org/10.1055/s-0044-1788135
[2024] Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study
DOI: https://doi.org/10.3390/biomedicines12071412
[2024] Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
DOI: https://doi.org/10.1016/j.jtho.2024.06.010
[2024] Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba8010
[2024] Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8011
[2024] Impact of EGFR mutation and types of treatment on the longitudinal recurrence risk in patients with completely resected non-small cell lung cancer: A combined analysis of two phase III studies (JIPANG and IMPACT).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8023
[2024] Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL
DOI: https://doi.org/10.1016/j.jtocrr.2024.100683
[2024] Abstract CT238: Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
DOI: https://doi.org/10.1158/1538-7445.am2024-ct238
[2024] A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulation
DOI: https://doi.org/10.1186/s40792-024-01851-8
[2023] BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.ccr-22-3901
[2023] Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
DOI: https://doi.org/10.1158/1538-7445.am2023-ct005
[2023] Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
DOI: https://doi.org/10.3390/cancers15092648
[2023] Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816
DOI: https://doi.org/10.1016/s0169-5002(23)00487-7
[2023] Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer
DOI: https://doi.org/10.2217/fon-2023-0007
[2023] Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
DOI: https://doi.org/10.1016/j.jtocrr.2023.100484
[2023] Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
DOI: https://doi.org/10.1016/j.xjon.2023.02.004
[2023] Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816
DOI: https://doi.org/10.1016/j.rmra.2022.11.184
[2023] MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
DOI: https://doi.org/10.1016/j.jtho.2023.10.017
[2023] OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
DOI: https://doi.org/10.1016/j.jtho.2023.09.071
[2023] OA12.05 Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
DOI: https://doi.org/10.1016/j.jtho.2023.09.070
[2023] P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study
DOI: https://doi.org/10.1016/j.jtho.2023.09.479
[2023] P1.08-05 On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models
DOI: https://doi.org/10.1016/j.jtho.2023.09.314
[2023] OA15.06 Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)
DOI: https://doi.org/10.1016/j.jtho.2023.09.083
[2023] Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
DOI: https://doi.org/10.1056/nejmoa2304875
[2023] NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR ‐mutated <scp>NSCLC</scp> : translational research of phase <scp>III IMPACT</scp> study
DOI: https://doi.org/10.1002/1878-0261.13542
[2023] LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
DOI: https://doi.org/10.1016/j.annonc.2023.10.055
[2023] LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
DOI: https://doi.org/10.1016/j.annonc.2023.10.053
[2023] Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer
DOI: https://doi.org/10.1200/jco.23.00179
[2023] Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
DOI: https://doi.org/10.1016/j.jtho.2023.08.029
[2023] The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative
DOI: https://doi.org/10.1016/j.jtho.2023.08.016
[2023] AEGEAN: A phase 3 trial of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
DOI: https://doi.org/10.1055/s-0043-1771092
[2023] Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
DOI: https://doi.org/10.1016/j.jtocrr.2023.100554
[2023] Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from <scp>CheckMate</scp> 816
DOI: https://doi.org/10.1111/cas.16030
[2023] Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.8521
[2023] Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.8524
[2022] Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial
DOI: https://doi.org/10.1158/1538-7445.am2022-ct012
[2022] Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
DOI: https://doi.org/10.1186/s13045-022-01299-z
[2022] Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.
DOI: https://doi.org/10.1200/jco.2022.40.17_suppl.lba8511
[2022] Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2022.100321
[2022] Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
DOI: https://doi.org/10.1016/s0140-6736(21)02333-3
[2022] International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials
DOI: https://doi.org/10.1016/j.jtho.2022.01.017
[2022] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.annonc.2022.02.003
[2022] [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].
[2022] Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
DOI: https://doi.org/10.1158/1538-7445.am2022-3255
[2022] 124P Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B N2 non-small cell lung cancer: SQUAT trial (WJOG 12119L)
DOI: https://doi.org/10.1016/j.iotech.2022.100236
[2022] <Case Report> A case of “a left middle lobe of lung” with a left superior vena cava in a patient who underwent lung cancer surgery
DOI: https://doi.org/10.15100/00023399
[2022] Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
DOI: https://doi.org/10.1016/j.jtho.2022.10.021
[2022] Changes in survival of patients with non–small cell lung cancer in Japan: An interrupted time series study
DOI: https://doi.org/10.1111/cas.15646
[2022] High levels of <scp>AXL</scp> expression in untreated <scp>EGFR</scp>‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
DOI: https://doi.org/10.1111/cas.15608
[2022] Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
DOI: https://doi.org/10.1016/j.jtocrr.2022.100404
[2022] Propensity score analysis for the efficacy of preoperative antibiotics in patients with resected primary lung cancer: Levofloxacin versus cefazolin
DOI: https://doi.org/10.1016/j.cson.2022.100005
[2022] SY20-4 Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data
DOI: https://doi.org/10.1016/j.annonc.2022.05.479
[2022] Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)
DOI: https://doi.org/10.1007/s10147-022-02193-x
[2022] 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
DOI: https://doi.org/10.1016/j.annonc.2022.07.1057
[2022] Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.esmoop.2022.100527
[2022] Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-
DOI: https://doi.org/10.2482/haigan.62.188
[2021] Résultats chirurgicaux de l’essai de phase 3 CheckMate 816 (CM 816) : Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néo-adjuvant du cancer bronchique non à petites cellules (CBNPC) résécable
DOI: https://doi.org/10.1016/j.rmra.2021.11.350

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（100 件）

科研費（0 件）

所属学会・役職（0 件）